CorMedix Inc (CRMD) concluded trading on Wednesday at a closing price of $11.62, with 7.22 million shares of worth about $83.91 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.97% during that period and on July 23, 2025 the price saw a gain of about 5.06%. Currently the company’s common shares owned by public are about 74.43M shares, out of which, 72.39M shares are available for trading.
Stock saw a price change of 4.40% in past 5 days and over the past one month there was a price change of -29.83%. Year-to-date (YTD), CRMD shares are showing a performance of 149.89% which increased to 43.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.61 but also hit the highest price of $17.43 during that period. The average intraday trading volume for CorMedix Inc shares is 1.97 million. The stock is currently trading -1.58% below its 20-day simple moving average (SMA20), while that difference is down -8.20% for SMA50 and it goes to 10.16% higher than SMA200.
CorMedix Inc (NASDAQ: CRMD) currently have 74.43M outstanding shares and institutions hold larger chunk of about 32.23% of that.
The stock has a current market capitalization of $864.87M and its 3Y-monthly beta is at 1.71. PE ratio of stock for trailing 12 months is 51.55, while it has posted earnings per share of $0.23 in the same period. It has Quick Ratio of 3.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRMD, volatility over the week remained 3.87% while standing at 4.28% over the month.
Stock’s fiscal year EPS is expected to rise by 455.24% while it is estimated to increase by 68.36% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 30, 2025 offering a Buy rating for the stock and assigned a target price of $20 to it. On March 07, 2025, Leerink Partners Initiated their recommendations, while on January 13, 2025, D. Boral Capital Initiated their ratings for the stock with a price target of $15. Stock get a Buy rating from Rodman & Renshaw on August 26, 2024.
